Shenyang Xingqi Cuts Atropine Drop Price, Boosting Access and Investor Interest
Shenyang Xingqi cuts its low‑dose atropine eye drop price by 1/5, boosting accessibility and investor interest while bolstering its eye‑care pipeline and market share.
- SHENYANG XINGQI PHARMACEUT
- China
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read